BioMarin Pharmaceutical Inc.
https://www.biomarin.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioMarin Pharmaceutical Inc.
Phase III Results Position Selecta/Sobi’s SEL-212 As Tough Competition For Krystexxa In Gout
Analysts pointed to SEL-212’s more favorable dosing and adverse event profile with fewer limitations that may harm compliance versus Krystexxa from Horizon, which is soon to be acquired by Amgen.
Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa
The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
- Other Names / Subsidiaries
-
- Huxley Pharmaceuticals, Inc.
- LEAD Therapeutics, Inc.
- Prosensa Holding N.V
- Zacharon Pharmaceuticals, Inc.
- ZyStor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice